- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8958
| Related Targets | Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Estrogen/progestogen Receptor Products | Elacestrant (RAD1901) Dihydrochloride Vepdegestrant (ARV471) MPP dihydrochloride Cholesterol Endoxifen HCl G15 Chrysin Licochalcone A AZD9496 PHTPP |
|
In vitro |
DMSO
: 95 mg/mL
(199.36 mM)
Ethanol : 95 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 476.51 | Formula | C24H28F4N6 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2222844-89-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1CC2=C(C=CC3=C2C=N[NH]3)C(N1CC(F)(F)F)C4=NC=C(NC5CN(CCCF)C5)C=C4 | ||
| Targets/IC50/Ki |
ER
|
|---|---|
| In vitro |
Camizestrant (AZD9833) is demonstrated to be a highly potent selective estrogen receptor degrader (SERD) that shows a pharmacological profile comparable to ICI-182780 in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. |
| In vivo |
Camizestrant (AZD9833) has potent in vivo activity in mouse xenograft models, and a stringent control of lipophilicity ensures that it has favorable physicochemical and preclinical pharmacokinetic properties for oral administration. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05551897 | Completed | Healthy Subjects |
AstraZeneca|Parexel |
October 4 2022 | Phase 1 |
| NCT05364255 | Completed | ER-positive HER2-negative Breast Cancer |
AstraZeneca|Quotient Sciences |
May 10 2022 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.